Cited 1 times in
Earliest total vascular damage index scores independently predict all-cause mortality in patients with ANCA-associated vasculitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박용범 | - |
dc.contributor.author | 송정식 | - |
dc.contributor.author | 안성수 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 구교진 | - |
dc.contributor.author | 하장우 | - |
dc.date.accessioned | 2024-05-23T03:21:03Z | - |
dc.date.available | 2024-05-23T03:21:03Z | - |
dc.date.issued | 2024-05 | - |
dc.identifier.issn | 0392-856X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199209 | - |
dc.description.abstract | Objectives: This study investigated whether the earliest total Vasculitis Damage Index (VDI) score could significantly predict all-cause mortality during follow-up in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Methods: This study included AAV patients who were first diagnosed at this hospital from 2001 to 2022. The earliest total VDI score was defined as the first VID assessed more than 3 months after AAV diagnosis in 93.5% of patients or after the first AAV presentation in 6.5% of patients. The optimal cut-off of the earliest total VDI score for all-cause mortality was obtained using the receiver operating characteristic curve. Results: The median age and earliest VDI score were 60.0 years (35.5% men), and 3.0. The most common damaged system in the earliest VDI was the pulmonary (55.3%) system. Among the AAV patients, 39 (13.3%) died. When the optimal cut-off of the earliest total VDI score for all-cause mortality was set at 3.0 (sensitivity 64.1%, specificity 75.2%), AAV patients with the earliest total VDI score ≥3.0 exhibited a significantly higher risk for all-cause mortality than those without (relative risk 6.090). AAV patients with the earliest total VDI score ≥3.0 exhibited a significantly lower cumulative patients' survival rate than those without. In the multivariable Cox hazards model analyses, not only the earliest total VDI score but also the earliest total VDI score ≥3.0 were independently associated with all-cause mortality. Conclusions: This study was the first to demonstrate that the earliest total VDI score could predict all-cause mortality during follow-up in AAV patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Clinical And Experimental Rheumatology S.A.S | - |
dc.relation.isPartOf | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / complications | - |
dc.subject.MESH | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / diagnosis | - |
dc.subject.MESH | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis* / mortality | - |
dc.subject.MESH | Cause of Death* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Predictive Value of Tests* | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Time Factors | - |
dc.title | Earliest total vascular damage index scores independently predict all-cause mortality in patients with ANCA-associated vasculitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Gyojin Koo | - |
dc.contributor.googleauthor | Jang Woo Ha | - |
dc.contributor.googleauthor | Sung Soo Ahn | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.identifier.doi | 10.55563/clinexprheumatol/6r9eus | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02233 | - |
dc.contributor.localId | A02824 | - |
dc.relation.journalcode | J00555 | - |
dc.identifier.eissn | 1593-098X | - |
dc.identifier.pmid | 38179702 | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | 박용범 | - |
dc.contributor.affiliatedAuthor | 송정식 | - |
dc.contributor.affiliatedAuthor | 안성수 | - |
dc.contributor.affiliatedAuthor | 이상원 | - |
dc.citation.volume | 42 | - |
dc.citation.startPage | 795 | - |
dc.citation.endPage | 802 | - |
dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, Vol.42 : 795-802, 2024-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.